Oct 17, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Aug 25, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Aug 25, 2025 05:21AM Gain Therapeutics (GANX) PT Lowered to $9 at BTIG

Aug 12, 2025 08:20AM Gain Therapeutics, Inc. (GANX) Misses Q2 EPS by 2c

Jul 3, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Apr 10, 2025 07:01AM Gain Therapeutics (GANX) Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287

Mar 14, 2025 07:45AM Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 7, 2025 07:10AM Scotiabank Starts Gain Therapeutics (GANX) at Sector Outperform

Feb 6, 2025 08:45AM Gain Therapeutics (GANX) CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Jan 8, 2025 08:01AM Gain Therapeutics (GANX) Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

Jan 7, 2025 07:01AM Gain Therapeutics (GANX) Appoints Gene Mack as CEO

Dec 6, 2024 08:42AM Roth/MKM Starts Gain Therapeutics (GANX) at Buy

Nov 25, 2024 06:51AM H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Oct 7, 2024 07:03AM Gain Therapeutics (GANX) Presents Preclinical GT-02287 Data

Oct 1, 2024 07:06AM H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Sep 30, 2024 12:58PM BTIG Reiterates Buy Rating on Gain Therapeutics (GANX)

Sep 3, 2024 08:29AM Maxim Group Reiterates Buy Rating on Gain Therapeutics (GANX)

Sep 3, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Sep 3, 2024 05:01AM BTIG Reiterates Buy Rating on Gain Therapeutics (GANX)

Aug 30, 2024 08:08AM Oppenheimer Reiterates Outperform Rating on Gain Therapeutics (GANX)

Aug 29, 2024 07:31AM Gain Therapeutics (GANX) Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Aug 14, 2024 06:51AM Oppenheimer Assumes Gain Therapeutics (GANX) at Outperform

Jul 11, 2024 10:34AM H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Jul 9, 2024 07:01AM Gain Therapeutics (GANX) Announces the Completion of Dosing in the Multiple Ascending Dose of the Phase 1 Study of GT-02287

Jul 2, 2024 06:36AM Gain Therapeutics (GANX) PT Lowered to $8 at H.C. Wainwright

Jun 27, 2024 04:08PM Gain Therapeutics (GANX) Appoints Gene Mack as Interim CEO

Jun 27, 2024 08:36AM Gain Therapeutics (GANX) Presents GT-02287 Data

Jun 14, 2024 05:59AM Gain Therapeutics (GANX) Prices 7.12M Share Offering at $1.35/sh

Jun 13, 2024 04:45PM Gain Therapeutics (GANX) Announces Proposed Share Offering